Wednesday, 18 Sep 2019

You are here

Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab

Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.

The ARTIS registry previously showed that women with a prior breast cancer who went on to receive a TNF inhibitor (TNFi) were not at great risk of breast cancer recurrence (http://buff.ly/2cfkrsv). They have also showed that cancers occurring after initiation of TNFi therapy do not have worse outcomes or reduced survival compared to cancer patients not exposed to TNFi (http://www.ncbi.nlm.nih.gov/pubmed/21305513).

The British Biologics Registry (BSRBR) examined 425 patients with a prior malignancy and assessed rates of recurrent malignancy in  patients treaed with either a TNFi, rituximab (RTX) or synthetic DMARDs (sDMARD).

Roughly one-quarter developed a new malignancy. The incident malignancy rates and adjusted hazard ratios (HR) were:

 Cancer Recurrence TNFiRTXsDMARD

Recurrent Malignancy Rate/1000OPY

33.324.753.8
Hazard Ratio0.550.43-
(95% CI) (0.35, 0.86)(0.10, 1.80-

 

The 17.0% of patients in the sDMARDs cohort had a recurrence of the same cancer in comparison with the 12.8% and the 4.3% in the TNFi and RTX cohorts.

These findings suggest that RA patients with a prior malignancy may be safetly treated with either a TNFi or RTX.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.